Unlocking the potential of antibody–drug conjugates for cancer therapy Article08 February 2021 Introduction Cancer has become the second greatest global health threat, accounting for approximately 10.0 million deaths from cancer occurred in 2020.1Cytotoxic agents based chemotherapy has been the main approach...
摘要:传统抗体偶联药物(antibody drug conjugates,ADC)通过将单克隆抗体与细胞毒性药物相结合,实现对癌细胞的精准打击,但在稳定性、靶向性、疗效及安全性等方面依然存在诸多不足。新型ADC,如双特异性、位点特异性、双有效载荷和前药型ADC,通过同时结合2个不同抗原或表位、选择更稳定的连接子、与抗体特定氨基酸位点偶联...
ADCs will likely become another important treatment strategy in advanced, pretreated lung cancer where current treatment options are limited. Both onocogen
Despite having a narrow therapeutic index, routine chemotherapy appears to be one of the salvage options for cancer treatment. These issues can be addressed by employing antibody-drug conjugates (ADCs) as a viable option for effective chemotherapeutic payload delivery and cancer cell targeting. The ...
The emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, ADCs aim to increase the therapeutic index, selectively targeti...
Cancer therapy with antibodies Suman Paul Maximilian F. Konig Shibin Zhou Nature Reviews Cancer (2024) Selective targeting of malignant T cells Charles E. de Bock Jan Cools Nature Cancer (2024) “Clone-specific” antibody-drug conjugates: an innovative strategy in the treatment of T-cell ...
antibody–drugconjugateresistancemonoclonalantibodiescancerimmunotherapyAntibody鈥揹rug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements ...
ADC Therapeutics is a commercial-stage oncology-focused biotechnology company developing ADCs for patients with hematological malignancies & solid tumors.
Antibody therapeutics have revolutionized the treatment of cancer over the past two decades. Antibodies that specifically bind tumor surface antigens can b... S Panowski,S Bhakta,H Raab,... - 《Mabs》 被引量: 665发表: 2014年 Potent antibody drug conjugates for cancer therapy. Significant progr...
Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated with novel highly potent cytotoxic payloads has permitted the development of more...